Crinetics Pharmaceuticals, Inc. (CRNX) · Sep 1, 2026 · Acquisition

Crinetics closes Vertex’s $10B buyout, ending its public-market story

$10B acquisition — Merger closed at the previously disclosed $85.00 cash-per-share consideration

Vertex has completed its $10 billion acquisition of Crinetics at $85 per share. The deal was already disclosed, so this is confirmation, not a surprise.

This is a closing confirmation, not a fresh deal surprise. Vertex completed the merger on September 1, 2026, after the transaction and its $85.00-per-share cash terms had already been disclosed on July 6. The filing says the merger became effective on the Closing Date (Introductory Note). 〔0〕

Shareholders receive cash, while the equity story ends. Each eligible Crinetics share was converted into the right to receive $85.00 in cash, and holders ceased to have stockholder rights other than the right to receive that consideration (Introductory Note; Material Modification to Rights of Security Holders).

The transaction fully removes Crinetics from the public market. Vertex now owns Crinetics as a wholly owned subsidiary; Nasdaq trading was suspended, and the company requested delisting and deregistration (Changes in Control; Delisting). 〔1〕

Operational control has transferred to Vertex. Crinetics’ directors resigned, its prior officers were removed, and Charles Wagner, Prasanna Thombre and Omar White became president, treasurer and secretary of the surviving subsidiary (Changes in Officers and Directors). 〔2〕

Net read: in line and fully priced in. The filing confirms the expected completion of the announced all-cash acquisition; it adds execution certainty but does not change the disclosed price, strategic terms, or shareholder outcome.

What to watch next

Form 25 delisting and Form 15 deregistration

Original filing on SEC EDGAR

More Crinetics Pharmaceuticals, Inc. news

Crinetics closes Vertex’s $10B buyout, ending its public-market story | CRNX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.